title: 18F-FCWAY and 18F-FDG PET in MRI-negative temporal lobe epilepsy.
abstract: BACKGROUND
  Positron emission tomography (PET) with (18)F-fluorodeoxyglucose (FDG) shows widespread hypometabolism even in temporal lobe epilepsy (TLE) patients with mesial temporal foci. (18)F-trans-4-fluoro-N-2-[4-(2-methoxyphenyl) piperazin-1-yl]ethyl-N-(2-pyridyl)cyclohexane carboxamide ((18)F-FCWAY) PET may show more specific 5-HT(1A)-receptor binding reduction in seizure initiation than in propagation regions. (18)FCWAY PET might be valuable for detecting epileptic foci, and distinguishing mesial from lateral temporal foci in MRI-negative patients with TLE.
  
  
  METHODS
  We performed (18)F-FCWAY-PET and (18)F-FDG-PET in 12 MRI-negative TLE patients who had had either surgery or subdural electrode recording, and 15 healthy volunteers. After partial volume correction for brain atrophy, free fraction-corrected volume of distribution (V/f1) measurement and asymmetry indices (AIs) were computed. We compared (18)F-FCWAY-PET and (18)F-FDG-PET results with scalp video electroencephalography (EEG), invasive EEG, and surgical outcome.
  
  
  RESULTS
  Mean (18)F-FCWAY V/f1, compared with normal controls, was decreased significantly in fusiform gyrus, hippocampus, and parahippocampus ipsilateral to epileptic foci, and AIs were significantly greater in hippocampus, parahippocampus, fusiform gyrus, amygdala, and inferior temporal regions. Eleven patients had clearly lateralized epileptogenic zones. Nine had congruent, and two nonlateralized, (18)F-FCWAY PET. One patient with bitemporal seizure onset had nonlateralized (18)F-FCWAY-PET. (18)F-FDG-PET showed congruent hypometabolism in 7 of 11 EEG-lateralized patients, bilateral hypometabolic regions in one, contralateral hypometabolism in one, as well as lateralized hypometabolism in the patient with bitemporal subdural seizure onset. Patients with mesial temporal foci tended to have lower superior and midtemporal (18)F-FCWAY V/f1 binding AI than those with lateral or diffuse foci.
  
  
  CONCLUSIONS
  (18)F-FCWAY-PET can detect reduced binding in patients with normal MRI, and may be more accurate than (18)F-FDG-PET.
authors.affiliation: Clinical Epilepsy Section, National Institutes of Health, Bethesda, Maryland 20892, USA.
authors.forename: Clarissa J
authors.initials: CJ
authors.lastname: Liew
authors.forename: Young-Min
authors.initials: YM
authors.lastname: Lim
authors.forename: Robert
authors.initials: R
authors.lastname: Bonwetsch
authors.forename: Sadat
authors.initials: S
authors.lastname: Shamim
authors.forename: Susumu
authors.initials: S
authors.lastname: Sato
authors.forename: Patricia
authors.initials: P
authors.lastname: Reeves-Tyer
authors.forename: Peter
authors.initials: P
authors.lastname: Herscovitch
authors.forename: Irene
authors.initials: I
authors.lastname: Dustin
authors.forename: Anto
authors.initials: A
authors.lastname: Bagic
authors.forename: Giampiero
authors.initials: G
authors.lastname: Giovacchini
authors.forename: William H
authors.initials: WH
authors.lastname: Theodore
mesh_terms: D000293:Adolescent; D000328:Adult; D000679:Amygdala / Q000000981:diagnostic imaging; D038481:Anterior Temporal Lobectomy; D001786:Blood Glucose / Q000378:metabolism*; D001921:Brain / Q000000981:diagnostic imaging; D003510:Cyclohexanes; D004292:Dominance, Cerebral / Q000502:physiology; D004569:Electroencephalography; D004833:Epilepsy, Temporal Lobe / Q000000981:diagnostic imaging* / Q000601:surgery; D005260:Female; D019788:Fluorodeoxyglucose F18; D005625:Frontal Lobe / Q000000981:diagnostic imaging; D006624:Hippocampus / Q000000981:diagnostic imaging; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008279:Magnetic Resonance Imaging; D008297:Male; D020534:Parahippocampal Gyrus / Q000000981:diagnostic imaging; D010879:Piperazines; D049268:Positron-Emission Tomography / Q000379:methods*; D044282:Receptor, Serotonin, 5-HT1A / Q000378:metabolism; D013702:Temporal Lobe / Q000000981:diagnostic imaging* / Q000601:surgery; D014741:Video Recording; D055815:Young Adult
chemical_list: D001786:Blood Glucose; D003510:Cyclohexanes; C493883:N-(2-(4-(2-methoxyphenyl)piperazino))-N-(2-pyridinyl) trans-4-fluorocyclohexanecarboxamide; D010879:Piperazines; D019788:Fluorodeoxyglucose F18; D044282:Receptor, Serotonin, 5-HT1A
references.citation: Boll Soc Ital Biol Sper. 1989 Jul;65(7):639-45
references.pmid: 2597418
references.citation: Arch Neurol. 1994 Sep;51(9):932-6
references.pmid: 8080394
references.citation: J Neurol Neurosurg Psychiatry. 1995 Oct;59(4):427-31
references.pmid: 7561924
references.citation: BMC Neurol. 2007;7:16
references.pmid: 17588263
references.citation: J Nucl Med. 2003 Jul;44(7):1006-12
references.pmid: 12843213
references.citation: Ann Neurol. 1991 Jul;30(1):31-6
references.pmid: 1929226
references.citation: Neurology. 1993 Jan;43(1):79-86
references.pmid: 8423915
references.citation: Mol Imaging Biol. 2002 May;4(3):245-52
references.pmid: 14537129
references.citation: Epilepsy Res. 2007 Jan;73(1):111-8
references.pmid: 17097271
references.citation: Epilepsia. 2007 Nov;48(11):2121-9
references.pmid: 17651417
references.citation: J Cereb Blood Flow Metab. 2003 Feb;23(2):249-60
references.pmid: 12571456
references.citation: Neuroimage. 2004 Jun;22(2):886-96
references.pmid: 15193619
references.citation: Neurology. 2003 Mar 11;60(5):749-56
references.pmid: 12629228
references.citation: Brain Res. 1997 Jan 16;745(1-2):96-108
references.pmid: 9037397
references.citation: Brain. 2004 Oct;127(Pt 10):2276-85
references.pmid: 15282217
references.citation: Epilepsia. 2006 Mar;47(3):499-503
references.pmid: 16529612
references.citation: Neuropharmacology. 1999 Aug;38(8):1083-152
references.pmid: 10462127
references.citation: J Neurosci Res. 2006 Nov 1;84(6):1292-302
references.pmid: 17099915
references.citation: Epilepsia. 2007 Aug;48(8):1526-30
references.pmid: 17442003
references.citation: J Cereb Blood Flow Metab. 2005 Jul;25(7):785-93
references.pmid: 15716853
references.citation: Neurology. 2004 Apr 27;62(8):1343-51
references.pmid: 15111672
references.citation: Epilepsia. 2003 Apr;44(4):559-64
references.pmid: 12681005
references.citation: J Nucl Med. 2005 Jul;46(7):1128-35
references.pmid: 16000281
references.citation: Arch Neurol. 2001 Jun;58(6):933-9
references.pmid: 11405808
references.citation: Epilepsia. 2001 Jan;42(1):130-2
references.pmid: 11207796
references.citation: Arch Neurol. 1997 Feb;54(2):129-36
references.pmid: 9041853
references.citation: Brain. 2004 Apr;127(Pt 4):900-13
references.pmid: 14985263
references.citation: Seizure. 2007 Sep;16(6):509-20
references.pmid: 17532231
references.citation: Brain Res. 2002 Nov 15;955(1-2):264-7
references.pmid: 12419546
references.citation: Neurology. 2003 Mar 11;60(5):736-7
references.pmid: 12629226
references.citation: Neurology. 1990 Sep;40(9):1420-6
references.pmid: 2392229
references.citation: Biol Psychiatry. 2007 Dec 1;62(11):1258-64
references.pmid: 17588547
references.citation: Brain Res. 2003 Mar 14;966(1):1-12
references.pmid: 12646302
references.citation: Neuroscience. 2005;135(3):803-13
references.pmid: 16129565